Education, not medical advice. This page explains how keratosis pilaris is generally treated and why the steps come in this order. It diagnoses nothing and recommends no therapy to anyone. Full disclaimer

Pick the pattern that matches

The over-the-counter start is shared; what happens after the clinic door depends on the pattern. Not sure? Start with the first; the route can be changed at any point.

Walking the route forRoughness on the arms, thighs or buttocks

Over the counter

Over the counterDay 1

Put the scrub down and take a baseline

Stop the one thing that makes this worse, and create the only reference point that will still be meaningful in three months.

Morning

Retire the brush, the mitt and the gritty scrub

Dry brushes, exfoliating gloves, loofahs, pumice, sugar and salt polishes, and anything sold as buffing the bumps away. All of them, rather than a reduced frequency — the goal is skin that is not being irritated when the keratolytic arrives, and a weekly scrub is still a weekly setback.
Photograph the area in daylight, close and from a distance

Two shots of the same patch, taken by a window rather than under a bathroom light, with something in frame for scale. Roughness photographs badly and colour photographs unreliably, which is exactly why a fixed reference matters more here than a recollection.

Evening

Decide which half is actually the complaint

Roughness, colour, or itch. The three answer to different treatments and the ladders diverge on this question, so naming it now prevents twelve weeks spent measuring the wrong thing. Most people find the honest answer is roughness, and are surprised.

What is normalTexture often feels marginally rougher in the first fortnight without the scrubbing, because the surface smoothing that friction produced has gone and the actual treatment has not started yet. That is expected.

Has the mechanical exfoliation stopped, and is there a dated baseline photograph?

Yes — scrub retired, photo takenThat is the reference point set. Go to step 2 ↓

Not yetBoth are worth doing before anything is bought. A keratolytic introduced onto scrubbed skin is the version of this plan that gets abandoned in week two.

Why this step

Mechanical exfoliation is both the default instinct and the thing most likely to have been making the condition look worse. Removing it first means the treatment below is being judged on its own rather than against a background of friction, and it means the skin is calm enough to tolerate an acid when one is introduced.

Four rules worth more than the choice of product

The failure mode: escalating at the half that does not answer

This condition has two components and they behave completely differently. The plugs respond to keratolytics — measurably, in a controlled trial, by about two-thirds over three months. The ring of colour around each follicle largely does not: the one properly controlled laser trial that improved roughness left redness statistically untouched, and the largest published series of the red variant reported minimal or no improvement across essentially every topical available. So the escalation people actually perform — a stiffer brush, a grittier scrub, a stronger acid, applied harder — is aimed at the half that does not answer, using the method most likely to inflame it further. The plan that works is unimpressive by comparison: one mild keratolytic, twice daily for three weeks, then once or twice a week for as long as it matters.

1 · Good to know Scrubbing harder is the one escalation that reliably backfires.
Friction cannot reach a plug seated inside the follicle, and what it does reach is the perifollicular skin producing the redness — so the method feels productive while making the untreatable half worse.
2 · Good to know Three weeks tells whether it is tolerated; twelve weeks tells how much it does.
The trial that produced the numbers ran for three months, and abandoning at week four is how a working treatment gets recorded as a failure.
3 · Good to know This is maintenance rather than a course.
Once or twice weekly application continues indefinitely, because the plugs re-form over weeks to months after treatment stops — which is the condition doing what it does, not the product having stopped working.
4 · Good to know Compare like seasons.
Four in five people report a seasonal swing and it usually runs worse in winter, so a result judged across December to June is measuring the calendar at least as much as the treatment.

Over the counterWeek 0–1

Change the shower before changing the shelf

Stop stripping the skin the treatment has to work on, which costs nothing and makes everything after it more tolerable.

Morning

Shorter, cooler showers and a non-soap wash

Hot water and detergent washes remove the lipids the barrier is already short of, and this condition sits disproportionately in people carrying an inherited barrier defect. A non-foaming or cream wash used only where it is needed is the change; the affected limbs mostly do not need washing with anything.
Browse all cleansers →
Emollient onto damp skin, within a few minutes

Applied while the skin is still damp it holds substantially more water than applied later to dry skin. Quantity is the variable that matters over an area covering both arms and both thighs, and the usual error is a tenth of what the job needs.
Browse all moisturizers →

Evening

The same emollient again, unfragranced

Fragranced body lotion is the most common avoidable irritant in this routine and the hardest to spot, because it is rarely dramatic — it simply keeps the skin slightly reactive. A plain ointment or thick cream is what the comparative trial actually tested.
Browse all moisturizers →

What is normalNothing at this stage should sting at all. An emollient that stings on intact skin is the wrong emollient, and the answer is a different one rather than persistence.

Has the shower routine changed and is an unfragranced emollient going on daily?

Yes — routine changedThe base is in place. Go to step 3 ↓

Not yetThis is worth a week on its own before the acid arrives. The step exists to make the next one tolerable, and skipping it is the most common reason the next one gets abandoned.

Why this step

In the one blinded trial to test it, a plain petrolatum-based ointment performed comparably to a prescription anti-inflammatory. That result is usually filed as a curiosity and it is better read as a finding: the barrier underneath is part of the condition, and treating it makes every keratolytic above work at lower irritancy for the same effect.

Over the counterWeeks 1–4

One keratolytic, twice daily

Introduce the treatment with the actual evidence behind it, and give it long enough to be judged.

Morning

Apply the keratolytic to the affected area

One product, not two. Ten to twelve per cent lactic acid has the best controlled result in this condition; urea at ten per cent or above is the alternative that treats the dryness at the same time; salicylic acid at two to five per cent is the option that reaches furthest into the follicle. The choice between them is about tolerance rather than potency.
Browse lactic acid products for keratosis pilaris →

Evening

The keratolytic again, then emollient over the top

Twice daily is what the trial used. The emollient goes on afterwards rather than instead — it does not cancel the acid out, and it is what keeps the skin comfortable enough for this to still be happening in March.
Browse all moisturizers →

What is normalMild stinging for the first minute or two, settling over the first fortnight, is expected. Stinging that lasts, spreads or worsens week on week is not tolerance building — it is usually a sign the skin is still being irritated by something else, most often shaving or residual scrubbing.

If it is not tolerated at twice dailyReducing to once daily is a legitimate plan rather than a compromise. So is applying the emollient first and the acid over it, which blunts the delivery slightly and improves the odds that the product is still in use three months later. A lower percentage used consistently beats a higher one used for a fortnight.

Has one keratolytic been in use for three weeks without escalating irritation?

Yes — it is establishedThe trial is running properly. Go to step 4 ↓

No — it stings or it lapsedDrop the frequency rather than the plan, and check the shaving and the water temperature before changing product. Most intolerance here is about what else the skin is being subjected to.

Why this step

This is the step with the numbers attached. In a randomised split-side trial, twice-daily ten per cent lactic acid reduced lesions by about two-thirds over three months and five per cent salicylic acid by about half, with mild local irritation the only adverse effect recorded. Nothing else available without a prescription has a result of that quality in this condition.

Over the counterWeeks 4–12

Hold it, and resist the additions

Let the treatment run long enough to be measured, without the extra products that make the result unreadable.

Morning

The same keratolytic, unchanged

Deliberately identical week to week. The trial that produced the two-thirds figure ran three months on one agent, and a routine that acquires a second acid in week six cannot be compared with it or with itself.
Browse lactic acid products for keratosis pilaris →

Evening

Photograph monthly, same window, same distance

Roughness changes slowly enough that daily observation reliably reports nothing. A monthly photograph from a fixed spot is what makes a real improvement visible and what stops a real improvement being abandoned as a failure.

What is normalA plateau somewhere around week six to eight is normal and is not the ceiling — improvement in the trial continued through the third month.

If only one thing happens this quarterKeep applying it. Consistency across twelve weeks does more here than any upgrade in strength, and the single most common pattern in this condition is a good product used for a fortnight, judged unsuccessful, and replaced by another good product used for a fortnight.

Has the same routine run unchanged for twelve weeks, with monthly photographs?

Yes — twelve weeks doneThat is a complete trial. Go to step 5 ↓

Not yetHold here rather than adding anything. The checkpoint below is only answerable if the routine it is judging has stayed still.

Why this step

Twelve weeks is where the numbers come from. Three weeks is enough to know a product is tolerable and doing something; it is not enough to know how much, and the difference between those two questions accounts for most of the products in most people's bathroom cupboards.

Over the counterWeek 12 onward

Drop to maintenance, and keep it there

Convert a twelve-week result into a permanent one, which is the step that separates this condition's successes from its relapses.

Morning

Keratolytic once or twice a week

Not stopped. Reduced. Guidance describes weekly or twice-weekly application once adequate improvement has been reached, and that schedule continues indefinitely because the plugs re-form without it.
Browse urea products for keratosis pilaris →
Emollient stays daily

This is the part that does not reduce. It is also the part most easily folded into an existing habit, which is why it tends to survive when the acid does not.
Browse all moisturizers →

Evening

Attach the weekly application to something that already happens

A fixed day rather than an intention. The characteristic failure of this condition is not a bad product — it is a good routine that quietly stops over a summer and is restarted in November with the bumps back and the conclusion drawn that the product stopped working.

What is normalIf the roughness creeps back at once weekly, the answer is twice weekly rather than a stronger product. The dial that matters here is frequency.

OptionalA seasonal adjustment is reasonable and expected: many people need twice weekly through the winter and once weekly or less through the summer, which matches the seasonal pattern four in five report.

Is there a specific, written maintenance schedule attached to a day of the week?

Yes — it is scheduledThat completes what is available without a prescription. Go to the checkpoint below ↓

Not yetWorth doing now rather than later. An intention to keep it up is the version that fails, and the failure takes six months to become visible.

Why this step

Every published account agrees on two things: nothing here is curative, and the improvement reverses when treatment stops. Maintenance is therefore not the aftercare of the treatment — it is the treatment, in its long-term form, and the only reason it is described as a separate step is that almost nobody is told about it.

Checkpoint12 weeks on the full routine

The twelve-week checkpoint

Compare photographs from the same window at the same distance, and judge roughness by touch with the back of the hand rather than by colour in a mirror. The two components move at different rates and the colour is the one least likely to have changed, so an overall impression is dominated by the half that was never going to respond.

Twelve weeks of one keratolytic used consistently on a moisturised base — what has the texture done?

Keep going“Noticeably smoother”Move to maintenance and change nothing else.

This is the expected result and it is the whole aim of the non-prescription tier. The risk from here is not relapse but drift: the improvement makes the routine feel unnecessary, it lapses over a summer, and the condition returns looking like a treatment failure. A weekly application attached to a fixed day is what prevents that, and it is worth more than any upgrade in product.

Second opinion“Better, but not enough”A reasonable point to ask what else exists.

Partial improvement after a complete twelve-week trial is a good position to bring to an appointment, because it establishes that the approach is right and the question is one of degree. It also makes the choice ahead a genuine one: a prescription retinoid works on the same problem by a different mechanism, and energy-based treatment is the tier with the most consistent published results and the largest bill.

To the clinic door“No real change in texture”This is the handover point.

Twelve weeks of consistent use with nothing to show for it is exactly the result this checkpoint exists to produce, and it is not evidence of anything done wrong. Two questions are worth raising at that appointment: whether a prescription topical is appropriate, and whether this is the right diagnosis — a stable field of plugs is characteristic, and anything that comes and goes, itches badly or arrived in adulthood deserves a second look.

Step back“More inflamed than at the start”Stop the acid and go back two steps.

Worse is not a weaker version of no-change and does not call for a stronger product. Skin that is redder and more irritated than it was twelve weeks ago is almost always still being scrubbed, shaved over, or treated with two actives at once. Returning to emollient alone for a fortnight and then reintroducing a single keratolytic at a lower frequency resolves most of it, and a persistent worsening is worth a clinician's eye rather than a change of brand.

Tools that make the check honest

Photo TrackerRoughness changes too slowly to notice day to day and this condition swings with the season, so a month-to-month impression is close to worthless.Ingredient DecoderThe whole non-prescription tier turns on a stated percentage, and the same acids appear at humectant strengths in products that will do nothing to a plug.Conflict CheckerThe rule here is one keratolytic at a time, and the commonest breach is accidental — a body lotion that already contains an acid, layered under one bought deliberately.Pregnancy-Safe CheckerPregnancy removes the retinoid rungs and leaves the keratolytics, but salicylic acid applied twice daily over a large surface is the case where a class answer is least useful.Derm Visit PrepThe appointment for this is worth more when it carries a specific question — which component is treatable, and what the next tier costs.

The clinic doorWhere the shelf ends

Where the over-the-counter pathway ends

On the shelfAvailable without seeing anyone

Behind the doorPrescribed, matched by examination, sometimes monitored

It ends at texture, and it ends without curing anything. Keratolytics measurably reduce the plugs and, used weekly, hold that reduction indefinitely — which is a genuine result and a smaller one than most product marketing implies. What the aisle cannot do is reach the colour: the perifollicular redness answers to vascular devices in a clinic and to essentially nothing on a shelf. What a clinician adds is a topical that corrects the keratinisation rather than dissolving its product, an anti-inflammatory for the days when the colour matters, and access to the device tier that two systematic reviews identify as the most consistently effective treatment there is.

What a visit looks like

With a prescription

Prescription topicalPrescription step 1

A prescription topical

The step up is a change of mechanism rather than of strength. A retinoid acts on the faulty keratinisation itself instead of dissolving what it produces, which is a better answer in principle and a harder one to keep using across an area this large.

The therapies at this stop

A fair trial
Three months, with frequency built up gradually rather than started daily — the first fortnight is where most of the abandonment happens.
Working looks like
Fewer palpable plugs and a smoother surface, developing over months rather than weeks.
Next stop if
Three months of a tolerated retinoid has not changed the texture, or the irritation makes consistent use across the affected area unrealistic.

In-office procedurePrescription step 2

Energy-based treatment for texture

The therapies at this stop

Prescription topicalPrescription step 1

Prescription topicals aimed at the inflammation

This rung is about the ring of colour rather than the plug, which changes the drug class entirely. A corticosteroid is deliberately bounded to a few days at a time, and the non-steroidal option exists precisely because this condition needs treating for years rather than weeks.

The therapies at this stop

A fair trial
Eight to twelve weeks for the non-steroidal options; a corticosteroid is judged within days because it is not continued beyond them.
Working looks like
Less background colour between the follicles, and a face or limb that flushes less readily.
Next stop if
Colour persists after an adequate topical trial, or the only thing that helps is a corticosteroid that cannot be continued safely.

In-office procedurePrescription step 2

Vascular laser and light

The therapies at this stop

Prescription topicalPrescription step 1

Treating the inflammation, not the plug

Where itch is the dominant symptom, the target is the inflammation rather than the keratin, and a short corticosteroid course settles it faster than any keratolytic. What follows the course matters more than the course: guidance is explicit that regular corticosteroid use on this condition risks thinning the skin, so the plan has to say what happens on day five.

The therapies at this stop

A fair trial
A defined short course for the corticosteroid, or eight to twelve weeks for a non-steroidal alternative used continuously.
Working looks like
Itch settling within days on a corticosteroid and over weeks on the alternatives, with the roughness largely unchanged either way.
Next stop if
The itch returns each time treatment stops, the area needing treatment keeps enlarging, or the picture looks increasingly like eczema rather than this condition.

Prescription topicalPrescription step 2

A retinoid, and a look at what sits underneath

The therapies at this stop

Prescription topicalPrescription step 1

Prescription topicals, with modest expectations

Topical treatment here aims at the active inflammation destroying the follicle rather than at appearance. The honest framing comes from the largest series: across twenty-one people treated with keratolytics, antibiotics, corticosteroids and retinoids, response was limited. Individual case reports of a retinoid halting progression exist and are the basis on which it is tried.

The therapies at this stop

A fair trial
Three to six months, judged on whether new lesions are still appearing rather than on how the existing ones look.
Working looks like
New lesions stopping. That is the realistic goal, and it is a meaningful one when what is being prevented is permanent.
Next stop if
New scarring or further hair loss continues despite topical treatment.

Prescription oral medicinePrescription step 2

Oral isotretinoin

The therapies at this stop

Staying clearThe end of the road

The part that decides whether any of it lasts

Whatever produced the improvement, the plugs return over weeks to months once treatment stops, and that is the condition behaving normally rather than the treatment having failed. What holds a result is a keratolytic once or twice a week, permanently, on skin that is being moisturised anyway — a schedule light enough that most people can keep it up and specific enough that it is worth writing down. The commonest pattern after a good twelve weeks is a gradual drift back to nothing over the following summer, followed by a puzzled restart in November. Booking the maintenance into an existing habit, rather than treating it as a course that finished, is the difference.

What holds the line

Coming back

Worth going back to a clinician if bumps start leaving pits or marks, if hair thins where they are, if the eyebrows or scalp become involved, if a field of them appears for the first time in adulthood, if the skin has become raw or paler in patches after prolonged treatment, or if any of them become painful or start draining. The ordinary form of this condition is stable and unremarkable, so anything that changes character is worth a second look rather than a stronger product.

Staying clearThe end of the road

Living with the half that does not fully answer

This variant is described as running from early childhood, without the atrophy or scarring of the harder forms, and often improving in adolescence and beyond. That trajectory is worth holding onto, because the treatments available in the meantime are modest and the temptation to keep escalating is strong. What is genuinely worth maintaining is short: the emollient, a mild keratolytic for the plugs, no mechanical exfoliation at all, and a corticosteroid kept firmly in the occasional-use box it belongs in. Where a laser course has helped, the reported durability is months, so this becomes a periodic expense rather than a completed treatment — a fact better costed at the start than discovered at the end.

What holds the line

Coming back

Staying clearThe end of the road

Where the emollient outlives everything else

In this group the emollient is not the thing that supports the treatment — over years it is the treatment, and the keratolytic becomes the occasional addition rather than the centrepiece. What that looks like in practice is a large tub bought in a quantity that would embarrass anyone treating a cosmetic problem, applied after every shower to skin still damp, indefinitely. Where eczema is present alongside, the two conditions are managed as one routine rather than two, and the flare plan for the eczema takes precedence whenever they disagree.

What holds the line

Coming back

Staying clearThe end of the road

After the process has been stopped

Success in this column looks unlike success anywhere else on the page: no new lesions, and everything already lost still lost. What follows is two separate conversations that are easily conflated. One is surveillance — whether the process is genuinely quiet, which is judged over years and by photographs rather than impressions, and which includes keeping the eye assessment current where it was indicated. The other is what to do about scarring that has stabilised, where resurfacing and, historically, dermabrasion have been used to improve the texture left behind. Neither restores a destroyed follicle, and the hair that has gone does not return.

What holds the line

Coming back

Through the clinic door Seeing a dermatologist Pack the bag, pick the questions, know the cost, then build the visit sheet.

This is diagnosed by looking, and the diagnosis is usually straightforward — which shifts what the appointment is actually for. In most systems the first conversation is with a family doctor, whose guidance describes this as having no cure and emphasises explanation, emollients containing urea or salicylic acid, and topical corticosteroid only for a few days at a time. Referral tends to follow one of three things: a presentation that scars, a diagnosis that does not fit, or a wish to discuss the device tier, which is generally classed as cosmetic and privately funded. Going in expecting a cure and coming out with a leaflet is the usual disappointment; going in with a specific question about the next tier is what makes the visit worth the trip.

1

Pack the bag

What turns a fifteen-minute appointment into a useful one.

0 of 6 packed
- Photographs from the same spot over several months, and from the same month in a previous year if any exist
- The names and stated percentages of everything already applied, and how long each ran
- A note of any mechanical exfoliation and how often, which is easy to forget and frequently relevant
- Whether the roughness, the colour or the itch is the thing that actually matters
- Any family history of the same skin, of eczema, or of very dry skin conditions
- Whether anything has ever scarred or left a mark, with a photograph if so
2

The questions to ask

Tap the ones worth taking in. They collect below, ready to copy or print.
Taking 0 questions in
3

Cost, and who to see

The non-prescription tier is inexpensive and, on a condition treated over years across a large surface area, the size of the container matters more than the price per gram. Prescription topicals are modest in cost where they are funded, though a retinoid applied to both arms and both thighs consumes a great deal more than the same product on a face. The device tier is the real expense: it is classed as cosmetic in most systems, is therefore paid for privately, and the published protocols treated a single limb — a full course over every affected area is a substantially larger commitment than the trials describe.

A family doctor can diagnose this and prescribe the topical options described here, and UK primary-care guidance covers it explicitly, including the caution that topical corticosteroids must not be used regularly on it. Asking for a dermatology referral is reasonable where lesions scar or hair is being lost, where the diagnosis is uncertain, or where a field of follicular bumps has appeared for the first time in adulthood. A referral purely for cosmetic laser treatment is generally not funded, which is worth establishing early rather than at the end of a wait.

How a clinician is reached varies by country, and for a condition classed as benign the first appointment is almost always with a family doctor rather than a specialist.

USFind a DermatologistAmerican Academy of Dermatology UKKeratosis pilarisNHS AustraliaKeratosis pilarishealthdirect Australia

From the Workshop · free, private, printable Derm Visit Prep: the whole visit on one sheet The appointment for this is worth more when it carries a specific question — which component is treatable, and what the next tier costs. Assembling the product history and the photographs beforehand is what turns a leaflet into a plan. Build the sheet

Pinned in the Square The other things people try 8 popular remedies, each stamped with how good its evidence really is.

This condition attracts an unusually large field of half-treatments, because it is visible, permanent and has no cure — which is exactly the combination the wellness market is built for. What follows is where the popular options actually stand.

The clinic library

The reference shelf behind the walk. Open any of it; none of it is needed to follow the route.

Understanding keratosis pilarisWhat is happening in the skin, and who this guide is for

Keratosis pilaris is a plumbing fault in the hair follicle. Instead of shedding, keratin accumulates and plugs the top of the follicular canal, and each plugged follicle becomes a small firm bump with a ring of pink around it. It is inherited in a substantial share of cases, runs in families, and typically arrives in childhood on the outer upper arms and the fronts of the thighs, sometimes the buttocks and the outer cheeks. It is not an infection, not a hygiene problem, and not acne — which matters, because all three of those assumptions lead somewhere unhelpful.

Who this guide is forAnyone with a permanent field of small rough bumps that feel like sandpaper and look worse in a photograph than in a mirror. It is also for the large group who have worked steadily up through gritty scrubs, dry brushes and stronger acids over several years, found the texture briefly better and the redness worse, and concluded the problem is that they have not yet found the right product.

How to read itThis page is a map rather than a diagnosis. The ordinary form is recognisable enough that most people identify it correctly, but a few things look similar and are handled differently: folliculitis, which is tender and comes and goes; the follicular pattern eczema can take on dry limbs; and, where bumps are followed by pitting, scarring or hair loss, a group of rarer variants that need a clinician rather than a keratolytic.

11Every therapy explainedWhat each one is, side effects, pregnancy

About the brand namesBrand names are what the pharmacy label says; the generic name underneath is what actually matters, and it is the part that stays true when a brand is discontinued or a region carries a different one. Where a region is missing from a card below, that reflects what could be verified rather than proof of absence.

Reading the labelWhere prescription cards below carry a label link, it points at a national medicines source rather than at a manufacturer. Every prescription treatment described on this page is used outside its licensed indication for this condition, so the leaflet will describe acne, psoriasis or eczema instead — which is routine and lawful, and means the document will not mention these bumps at all.

On the shelfNo prescription needed · 5

Over the counter Lactic and glycolic acid Alpha hydroxy acid keratolytics Strong evidence Generally fine in pregnancy

The best-evidenced thing available without a prescription for this condition, and the topical class the most recent systematic review names first.

At the shelf, look for

A body lotion or cream stating a percentage — around ten to twelve per cent lactic acid, or eight to ten per cent glycolic.

A stated number is the whole point, because these acids are also used at one or two per cent purely as humectants and those products will do nothing to a plug. Ammonium lactate is lactic acid buffered to a gentler pH and appears on labels in place of it. A lotion or cream base beats a serum for an area this size — the arms and thighs together are a large surface, and a product that runs out in a fortnight will not survive as maintenance.

Body scrubs that list an acid somewhere below the abrasive. The grit is doing the opposite of what the acid is for, and rinse-off contact of thirty seconds is not a treatment.

Browse every lactic acid product in the Market →

How it works

These acids break the ionic bonds holding corneocytes together at the mouth of the follicle, so the plug loosens and sheds rather than accumulating. Lactic acid is also a natural moisturising factor, which means it draws water into the stratum corneum while it works — a dual action that matters on skin that is usually dry underneath.

The usual course

Twice daily for at least three weeks to know whether it is tolerated and doing anything, twelve weeks before judging the size of the result, then once or twice weekly indefinitely.

Where it sits on the route

It leads the non-prescription tier because it has the only head-to-head controlled result in this condition and because it is the agent the current systematic review puts first. It is also the one most likely to be still in use in five years, which for a condition treated by maintenance is the property that decides outcomes.

Side effects people notice

Stinging on application, particularly on freshly shaved or recently exfoliated skin
Mild local irritation, which was the only adverse effect recorded in the controlled trial
Dryness if used without an emollient alongside it

Worth knowing before starting

Applied to skin that has just been scrubbed or shaved, the sting is severe enough that most people abandon it — the order of operations matters more than the strength
Alpha hydroxy acids increase sensitivity to ultraviolet light, which matters for arms and shoulders in summer
A percentage that is not printed on the box is a percentage that is not worth paying for

Topical alpha hydroxy acids on the body are generally regarded as compatible with pregnancy and breastfeeding, with negligible systemic absorption at these concentrations. They become proportionally more important then, since the retinoid rungs above are withdrawn.

The evidence

In a randomised split-side trial of fifty people, twice-daily ten per cent lactic acid reduced lesions by about two-thirds over three months and five per cent salicylic acid by about half, both statistically significant, with improved stratum corneum conductance maintained into follow-up. A 2025 systematic review names lactic and glycolic acids as the preferred topical agents.

Epidermal permeability barrier in the treatment of keratosis pilaris (opens in a new tab), Dermatology Research and Practice 2015
Keratosis pilaris: a systematic review of the literature and strategies for optimal treatment (opens in a new tab), European Journal of Dermatology 2025

Over the counter Urea creams Keratolytic humectant Promising Generally fine in pregnancy

One of two topical options named in UK primary-care guidance for this condition, and the one that treats the dryness underneath at the same time.

At the shelf, look for

Ten per cent or higher, stated on the front, in a cream rather than a light lotion.

The percentage decides what the product is. Below about ten per cent urea behaves as a humectant and holds water in the skin; at ten and above it starts breaking down the keratin itself, and the higher strengths sold for heels and elbows are usually too aggressive for the arms. Preparations combining urea with salicylic acid exist and are the traditional compounded approach, pairing an emollient base with the keratolytic in one step.

Urea buried in an ingredient list with no percentage anywhere on the packaging, which is common and which almost always means a humectant-level dose.

Browse every urea product in the Market →

How it works

Urea disrupts hydrogen bonding in keratin, which softens and loosens the plug, while simultaneously binding water in the stratum corneum. That combination suits this condition specifically, because the skin the plugs form in is usually dry and a purely exfoliating approach leaves it drier.

The usual course

Twice daily initially, then dropped to once or twice a week once the roughness has settled. Many people end up using it as their ordinary body moisturiser and never formally stop.

Where it sits on the route

It shares the first rung with the alpha hydroxy acids rather than sitting below them, because the choice between the two is about skin dryness and tolerance rather than potency. Where the skin underneath is very dry, this is frequently the one that gets used consistently, and consistency is what this condition is decided by.

Side effects people notice

Stinging on broken or shaved skin, which is more pronounced at the higher percentages
A faintly ammoniac smell in some preparations
Temporary redness after application on already-inflamed skin

Worth knowing before starting

High-strength preparations sold for callused heels are not intended for the arms and are a common cause of an avoidable reaction
Combining it with a second acid on the same skin is how tolerance problems start; one keratolytic at a time is the rule
It is not a substitute for an emollient on very dry skin so much as a version of one that also works

Topical urea is considered compatible with pregnancy and breastfeeding and is widely used in that setting for dry-skin conditions. Nothing about this condition changes that assessment.

The evidence

Named in UK primary-care guidance alongside salicylic acid as an acceptable topical option, and used as the active comparator in a split-body laser trial rather than as a placebo — which is a fair indication of how it is regarded. The direct trial evidence for urea alone in this condition is thinner than for lactic acid.

Clinical and dermoscopic evaluation of fractional carbon dioxide laser in management of keratosis pilaris in Egyptian type skin (opens in a new tab), Journal of Cosmetic Dermatology 2020

Over the counter Salicylic acid Beta hydroxy acid keratolytic Strong evidence Pregnancy: case by case

The other agent named in UK primary-care guidance, and the one whose oil solubility suits a condition that lives inside the follicle.

At the shelf, look for

Two to six per cent in a leave-on lotion or cream for the body.

Being oil-soluble, it penetrates the follicle rather than working only across the surface, which is the specific argument for it in a follicular condition. Two per cent is the everyday strength; the trial that produced the numbers used five. Preparations compounding it into a urea base exist and are the traditional approach for widespread disease, combining the keratolytic with something that treats the dryness around it.

Medicated body washes built on salicylic acid. Contact time is measured in seconds in a shower, and this needs to be left on to do anything.

Browse every salicylic acid product in the Market →

How it works

It dissolves the intercellular cement between corneocytes and, unlike the water-soluble acids, partitions into the sebum-rich follicular canal where the plug actually sits. That is a mechanistic argument rather than a demonstrated advantage — in the one head-to-head trial it came second.

The usual course

Twice daily for the first three weeks, reviewed at twelve, then reduced to a weekly or twice-weekly application held indefinitely.

Where it sits on the route

It sits alongside the other keratolytics rather than above or below them. The mechanistic case for reaching into the follicle is good and the head-to-head result put it second, so it is presented as an equal option chosen on tolerance rather than as a step up.

Side effects people notice

Dryness and fine flaking, particularly in winter
Stinging where the skin is already irritated
Redness on skin that has been scrubbed

Worth knowing before starting

Applying it over a very large body-surface area repeatedly is the one situation where systemic absorption is worth a thought, and it is worth raising with a pharmacist where the area is extensive
Not combined with another acid on the same skin
Avoided on skin that is currently raw from mechanical exfoliation, which is the commonest reason it seems intolerable

Low-concentration topical salicylic acid on limited areas is generally regarded as acceptable in pregnancy, but this condition often involves a large surface area applied twice daily, which is the situation where the usual reassurance is least applicable. Worth confirming with whoever is providing antenatal care rather than assuming from the class.

The evidence

In the randomised split-side trial, five per cent salicylic acid twice daily reduced lesion counts by about half over three months — statistically significant, and behind ten per cent lactic acid over the same period. It is one of two topicals named in current UK primary-care guidance.

Epidermal permeability barrier in the treatment of keratosis pilaris (opens in a new tab), Dermatology Research and Practice 2015
Practical management of widespread, atypical keratosis pilaris (opens in a new tab), Journal of the American Academy of Dermatology 1984

Over the counter Plain emollients and the bathing routine Barrier support Promising Generally fine in pregnancy

The layer everything else is applied over, and — on the evidence — a more active participant than it is usually given credit for.

At the shelf, look for

An unfragranced ointment or thick cream, and a non-soap wash to replace whatever is currently being used.

The thing worth knowing about this category is that it outperformed expectations in the one trial that tested it properly: a plain petrolatum-based ointment was compared against a prescription anti-inflammatory and the two were not significantly different. Applied to skin still damp from the shower it holds considerably more water than applied to dry skin. Quantity matters more than formulation on an area this size.

Body washes marketed for this condition on the strength of a token acid. The wash is the part of the routine that should be doing the least.

Browse every petrolatum product in the Market →

How it works

Reducing water loss through the barrier softens the stratum corneum, which makes the plugs easier to shed and makes every keratolytic above work at a lower effective irritancy. In skin carrying a barrier defect, which a substantial share of this population does, that is treating the substrate rather than comforting it.

The usual course

Daily, permanently, and independently of whatever else is running. This is the rung that never stops.

Where it sits on the route

It sits on the foundation rung rather than in supporting care because of the trial above. A category that holds its own against a prescription ointment in a blinded comparison has earned a place in the treatment list, whatever its reputation as a comfort measure.

Side effects people notice

Heavier ointments are greasy enough that they are usually confined to night-time use on the limbs
Occlusive products on the trunk can provoke folliculitis in a minority

Worth knowing before starting

Applied to dry skin an hour after a shower it does a fraction of the job it does on damp skin
Fragranced body lotions are the most common avoidable irritant in this routine
Very hot showers and long soaks strip the barrier faster than any emollient replaces it

Emollients and non-soap washes are compatible with pregnancy and breastfeeding without qualification, and this rung carries more of the load then because the retinoid options above are withdrawn.

The evidence

In a double-blind comparative trial of twenty-seven people, a petrolatum-based ointment and prescription tacrolimus ointment both improved the condition and were both well tolerated, with the difference between them not reaching statistical significance. Emollient use is standard in every published description of management.

A comparative trial comparing the efficacy of tacrolimus 0.1% ointment with Aquaphor ointment for the treatment of keratosis pilaris (opens in a new tab), Pediatric Dermatology 2011

Over the counter Gentle mechanical exfoliation, and where it stops Physical exfoliation Limited evidence Generally fine in pregnancy

The step nearly everyone tries first, included here because its limits are the most useful thing on this page rather than because of what it achieves.

At the shelf, look for

A soft synthetic sponge or cloth, if anything at all. Not a brush, not a pumice, not a sugar or salt scrub.

The published support for this is a single 1984 report in which a polyester sponge was used to apply a compounded keratolytic, and the mechanical element there was a delivery method rather than the treatment. Used lightly, once or twice a week, on skin that is not already irritated, a soft sponge is defensible. Used daily with pressure, it is the single most reliable way to make this condition look worse than it did before treatment started.

Dry brushes, exfoliating gloves, gritty body polishes and anything marketed as buffing the bumps away. The plug is inside the follicle and cannot be abraded off the top of it.

How it works

Friction removes surface corneocytes, which briefly smooths the skin and does very little to a plug seated inside the follicular canal. What it reliably does reach is the perifollicular skin, where mechanical irritation adds inflammation to the exact component of this condition that no treatment on the page removes.

The usual course

At most once or twice a week, briefly and without pressure, and stopped entirely at the first sign of soreness.

Where it sits on the route

It appears on the foundation rung as a bounded option rather than being left off the page. Omitting it would not stop anyone doing it — it is the default instinct for a rough texture — and stating its ceiling plainly is more use than pretending the category does not exist.

Side effects people notice

Perifollicular redness that outlasts the smoothing by days
Post-inflammatory marks, which last longer and read browner on richer skin tones
A cycle in which the roughness returns faster after each session, prompting more frequent scrubbing

Worth knowing before starting

Escalating the abrasion is the characteristic mistake in this condition, and it targets the half that does not respond
Never on the same day as a keratolytic, and never before shaving
If the skin is pink for more than an hour afterwards, the method was too aggressive regardless of how it felt at the time

Physical exfoliation raises no pregnancy considerations. The caution about pressure and frequency is unchanged, and applies for the same reasons it always does.

The evidence

One report from 1984 describes a polyester sponge used to apply a compounded salicylic-acid-in-urea preparation to widespread disease, with clearance in most patients over two to three weeks. Current UK primary-care guidance mentions exfoliation with a buff as something patients may wish to try, alongside an explicit statement that no cure exists.

Practical management of widespread, atypical keratosis pilaris (opens in a new tab), Journal of the American Academy of Dermatology 1984

Prescribed, applied to the skinCreams, gels and lotions · 3

Prescription · on the skin Topical retinoids Prescription topical retinoids Promising Avoid in pregnancy

The prescription topical with a randomised trial behind it in this condition, and the only agent shown to improve all three of roughness, redness and itch together.

How it works

Retinoids normalise the keratinisation of the follicular lining — the process that is going wrong here — rather than dissolving the plug after it has formed. That is a mechanistically better answer than a keratolytic and a considerably harder one to tolerate, and the difficulty is why it sits above rather than beside the acids.

The usual course

Introduced at a low frequency and built up over weeks, with three months a fair assessment period. Irritation in the first fortnight is the usual reason it is abandoned.

Where it sits on the route

It occupies the first prescription rung because it addresses the fault rather than its product, and because it is the only topical here with a randomised result covering the colour component as well as the texture. It sits above the acids rather than beside them purely on tolerability.

Side effects people notice

Dryness, peeling and redness, particularly in the first month
Increased sensitivity to sunlight on areas that are frequently uncovered
A transient worsening in appearance before improvement

Worth knowing before starting

Contraindicated in pregnancy as a class
The area involved is often large, and applying a retinoid across both arms and both thighs is a considerably bigger undertaking than treating a face
Building up frequency slowly is what determines whether it is still in use at three months

Topical retinoids are avoided in pregnancy and when trying to conceive, and tazarotene in particular carries a specific contraindication. Where treatment is wanted during pregnancy, the ladder restarts at the keratolytic tier, which is where most of the achievable benefit sits in any case.

What it is called at the pharmacy

Generic nameTopical retinoids

United KingdomTretinoin and adapalene preparations are prescribed for this off-label; tazarotene cream is not routinely stocked

A region missing here reflects what could be verified this session rather than what is available.

The evidence

A randomised, placebo-controlled, double-blind study of thirty-three people using tazarotene 0.05% cream on the arms reported statistically significant improvement in itch, redness and roughness. That trial was published as a conference abstract rather than a full paper, which is a real limitation on how much weight it carries.

Tazarotene 0.05% cream for the treatment of keratosis pilaris, Journal of the American Academy of Dermatology 2004
Treatment of keratosis pilaris and its variants: a systematic review (opens in a new tab), Journal of Dermatological Treatment 2022

Prescription · on the skin Topical tacrolimus Non-steroidal anti-inflammatory topical Limited evidence Pregnancy: case by case

A non-steroidal anti-inflammatory ointment borrowed from eczema practice, used here where the inflammatory ring around the follicle is the complaint and where a corticosteroid cannot be continued.

How it works

It blocks calcineurin in T cells and so suppresses the local inflammatory signalling, without the skin thinning that limits how long a corticosteroid can be used on the same area. In a condition treated over years on a large surface, that difference is the entire reason the class is considered.

The usual course

Twice daily, reviewed at eight to twelve weeks, and generally used on a limited area rather than across every affected surface.

Where it sits on the route

It shares the first prescription rung with the retinoids rather than sitting above them, because the two are chosen for different halves of the problem — one for the plug, one for the inflammation around it — and no trial has compared them.

Side effects people notice

Burning and stinging in the first few days of use, which is the commonest reason it is stopped
Warmth and flushing on application, more noticeable with alcohol
Sensitivity to sunlight on treated areas

Worth knowing before starting

Used outside its licensed indication here, so the leaflet will describe eczema
The class carries a boxed warning in some countries based on theoretical long-term risk, which a prescriber will discuss
Cost becomes the practical constraint when the area involved is both arms and both thighs

Systemic absorption from intact skin is low, but human pregnancy data are limited and the surface areas involved in this condition can be large. Whether it is used is a prescriber's judgement made alongside antenatal care rather than a class rule.

What it is called at the pharmacy

Generic nameTopical tacrolimus

United StatesProtopic — tacrolimus ointment 0.03% and 0.1%

A region missing here reflects what could be verified this session rather than what is available.

The evidence

A double-blind comparative trial of twenty-seven people found tacrolimus 0.1% ointment more likely than a plain petrolatum-based ointment to produce major improvement, but the difference did not reach statistical significance and both arms improved. A systematic review lists it among the topicals with supporting evidence.

A comparative trial comparing the efficacy of tacrolimus 0.1% ointment with Aquaphor ointment for the treatment of keratosis pilaris (opens in a new tab), Pediatric Dermatology 2011
Treatment of keratosis pilaris and its variants: a systematic review (opens in a new tab), Journal of Dermatological Treatment 2022

Prescription · on the skin Short-course topical corticosteroid Topical corticosteroid, time-limited Limited evidence Pregnancy: case by case

A few days of an anti-inflammatory cream to take the colour down, used deliberately as a short intervention and explicitly not as ongoing treatment.

How it works

Corticosteroids suppress the perifollicular inflammation that produces the redness, which is why they work quickly on the colour and do nothing at all to the plug. The same suppression, continued, thins the skin — and thinned skin around a follicular condition is a worse starting point than the one being treated.

The usual course

A few days at a time, then stopped, with treatment returning to keratolytics once the inflammation has settled. It is not a maintenance option and is not intended to become one.

Where it sits on the route

It sits on the prescription tier as a bounded tool rather than as a rung anyone climbs to permanently. Its honest description is a treatment for a fortnight in someone's life rather than a treatment for the condition.

Side effects people notice

Skin thinning with repeated or prolonged use, which is the limiting problem rather than a remote risk
Stretch marks where the skin is under tension, particularly on the upper arms and thighs
Rebound redness when a longer course is stopped abruptly

Worth knowing before starting

Regular use on this condition is specifically advised against in primary-care guidance
Potency and duration on the face differ from the limbs and are a prescriber's decision
Its rapid effect on colour makes it the easiest treatment here to overuse, which is precisely why the duration is stated before the benefit

Short courses of low- to mid-potency topical corticosteroid over limited areas are commonly regarded as acceptable in pregnancy, with potency and quantity the factors that matter. Anything beyond a brief course belongs with whoever is providing antenatal care.

What it is called at the pharmacy

Generic nameShort-course topical corticosteroid

United KingdomClobetasone butyrate 0.05% cream is the example named in primary-care guidance for a few days' use before an occasion

A region missing here reflects what could be verified this session rather than what is available.

The evidence

Described in current UK primary-care guidance as an option for a few days at a time where perifollicular redness is significant, with an explicit warning against regular use because of skin atrophy. In published series of the harder variants, corticosteroids were among the treatments producing limited response.

Clinical findings, cutaneous pathology, and response to therapy in 21 patients with keratosis pilaris atrophicans (opens in a new tab), Archives of Dermatology 1994

Prescribed, taken by mouthTablets and capsules · 1

Prescription · by mouth Oral isotretinoin Systemic retinoid Limited evidence Avoid in pregnancy

Reserved entirely for the scarring variants, where the goal is halting progression rather than improving appearance — and where even that is inconsistent.

How it works

Isotretinoin alters follicular keratinisation and shrinks sebaceous glands, and it is the systemic agent with the broadest effect on follicular disease. Why it helps some scarring variants and not others is not explained, and the published record reflects that unpredictability rather than resolving it.

The usual course

Months rather than weeks in the published reports, at doses below those used for severe acne, with the endpoint defined as no new lesions rather than clearance of existing ones.

Where it sits on the route

It appears only at the top of the scarring column, because that is the only place the risk is arguable. On a cosmetic condition affecting the backs of the arms it would be an indefensible trade, and saying so is more useful than listing it as an option.

Side effects people notice

Dryness of lips, eyes and nasal lining, which is close to universal
Muscle aches and occasional disturbance of night vision
Changes in blood lipids and liver enzymes, which is what the monitoring covers
Mood changes, discussed at every consultation as part of the standard process

Worth knowing before starting

Cannot be taken during pregnancy at any dose, and the prevention programme runs alongside every prescription
It has no role in the ordinary form of this condition, where the risk-to-benefit calculation is not close
Reported results in the scarring variants are inconsistent, and one series described worsening in a treated patient

MonitoringBlood tests before and periodically during treatment, together with the pregnancy testing and contraception requirements applying to everyone who can become pregnant.

The birth defects isotretinoin causes are severe and well characterised, which is why prescribing sits inside a mandatory programme of testing and contraception spanning the period before, throughout and after a course. Nothing about a low dose or a cosmetic indication relaxes any of that.

What it is called at the pharmacy

Generic nameOral isotretinoin

United KingdomInitiated by a consultant dermatologist, with the pregnancy-prevention programme applying in full whatever the dose

A region missing here reflects what could be verified this session rather than what is available.

The evidence

The record is case reports pointing in both directions. Individual reports describe progression of atrophy halted and hair regrowth in the scarring variants; a series of twenty-one people with keratosis pilaris atrophicans found response to keratolytics, antibiotics, corticosteroids and retinoids alike to be limited, and among those given isotretinoin most did not improve.

Clinical findings, cutaneous pathology, and response to therapy in 21 patients with keratosis pilaris atrophicans (opens in a new tab), Archives of Dermatology 1994
Keratosis pilaris atrophicans. One heterogeneous disease or a symptom in different clinical entities? (opens in a new tab), Archives of Dermatology 1994

Done in the clinicProcedures and devices · 2

Done in the clinic Resurfacing and non-ablative lasers Energy-based devices for texture Promising Pregnancy: case by case

The tier with the most consistent published results in this condition, aimed squarely at the roughness rather than the colour.

How it works

These devices work by controlled thermal injury to the follicle and surrounding dermis, prompting remodelling of the tissue that is producing the plug rather than removing the plug itself. That is a different proposition from anything topical, and it is why results persist for months rather than days after treatment stops.

The usual course

Three to four sessions at roughly four-week intervals in the published trials, with assessment several weeks after the last. Durability beyond a few months is not established for any device.

Where it sits on the route

It sits at the top of the texture column because two systematic reviews put it there, and because it is the only tier that produces a result which outlasts the treatment by months. It sits at the top rather than earlier because it is expensive, uncomfortable and not curative.

Side effects people notice

Post-inflammatory pigment change, which caused two withdrawals in the diode laser trial
Transient redness and swelling for days after each session
Discomfort during treatment over a large area

Worth knowing before starting

Pigment change is the risk that matters, and it is higher on richer skin tones — practitioner experience with the specific skin tone predicts the result more reliably than the device does
Almost always paid for privately, since this is classed as cosmetic in most systems
The trials treated a single arm; treating every affected area is a substantially larger commitment than the published protocols describe

Elective energy-based treatment is usually deferred during pregnancy — not because harm has been shown, but because there is nothing to gain by accepting an unquantified risk for a cosmetic benefit that will still be available afterwards.

The evidence

Several sham-controlled and split-body randomised trials support this tier: a 1064 nm Nd:YAG laser significantly reduced instrument-measured roughness over four sessions against sham irradiation, and an 810 nm diode laser improved roughness in a split-body placebo-controlled trial. Two systematic reviews conclude that energy-based treatment is the most consistently effective modality, with the Nd:YAG named specifically.

Innovative 1064-nm Nd:YAG Laser Significantly Improves Keratosis Pilaris, A Randomized, Double-Blind, Sham-Irradiation-Controlled Trial (opens in a new tab), Lasers in Surgery and Medicine 2020
Treatment of keratosis pilaris with 810-nm diode laser: a randomized clinical trial (opens in a new tab), JAMA Dermatology 2015

Done in the clinic Vascular laser and light Energy-based devices for erythema Limited evidence Pregnancy: case by case

The only tier on this page that reliably addresses the redness, and the reason the colour-led column exists separately from the texture-led one.

How it works

Pulsed dye, potassium titanyl phosphate and broad-spectrum intense pulsed light are absorbed preferentially by haemoglobin, which lets them target the dilated perifollicular vessels producing the colour while leaving the surrounding skin largely alone. Nothing applied to the skin does this, which is why the redness sits outside the reach of the entire topical tier.

The usual course

Two to eight sessions in the reported series, spaced several weeks apart, with reported durability of months rather than years.

Where it sits on the route

It sits at the top of the colour column and nowhere else. Vascular devices do nothing for the plugs, and putting them on the texture ladder would offer an expensive answer to a question they do not address.

Side effects people notice

Bruising after pulsed dye laser at the settings that clear vessels fastest
Post-inflammatory hyperpigmentation, reported after treatment in this condition
Temporary swelling and redness for several days

Worth knowing before starting

The evidence here is weaker than for the texture-directed devices, and expectations should be set from the case series rather than from the marketing
Facial treatment on a young person is a different conversation from treating an arm, and is usually a specialist one
Cosmetic classification means this is rarely funded

As with the resurfacing devices, elective vascular laser is customarily postponed during pregnancy on the grounds that the benefit is cosmetic and can wait, rather than because a specific harm has been demonstrated.

The evidence

The published experience is small series and case reports rather than randomised trials — a systematic review of light and laser treatment across all variants of this condition found seventeen studies covering 175 patients in total. Reported outcomes for erythema are consistently good and the evidence supporting them is thin; intense pulsed light has one sham-controlled trial behind it.

Light and Laser Treatments for Keratosis Pilaris: A Systematic Review (opens in a new tab), Dermatologic Surgery 2020
Intense Pulsed-light Therapy Significantly Improves Keratosis Pilaris: A Randomized, Double-blind, Sham Irradiation-controlled Trial (opens in a new tab), The Journal of Clinical and Aesthetic Dermatology 2019

4Telling the patterns apartAnd what else looks like keratosis pilaris

There is no severity scale in general use, and the useful description is not how bad it is but which of its two components dominates. Every case is some mixture of plugged follicles and the redness around them, and those two respond so differently to treatment that describing a case without separating them makes the result unreadable.

The patterns Tap a card to see what it looks like

What changes the plan, whatever the pattern

Eczema, very dry skin, or a family history of bothThe association is real and it is genetic rather than coincidental: in a study of five hundred people with atopic dermatitis, keratosis pilaris tracked strongly with palmar hyperlinearity and with a filaggrin loss-of-function variant, both markers of the same barrier defect. Practically, it means the emollient is not an optional comfort layer here — it is treating the substrate the plugs are forming in, and the keratolytic works better on skin that is already being kept hydrated.
WinterFour in five people in the only natural-history survey reported a seasonal swing, and among those it split almost evenly between improving in summer and worsening in winter. That has two consequences worth knowing in advance: a treatment started in October is fighting the season as well as the condition, and a result judged in July may be flattered by it. Comparing like months is what keeps the assessment honest.
Diabetes, higher body weight, or signs of androgen excessIt appeared in twelve per cent of young people with type 1 diabetes against one and a half per cent of matched controls in one study, and it is described alongside higher body mass index and androgen excess. None of that changes the topical plan, and it does change what an appointment is for: extensive or unusually abrupt disease is one of the few situations in which a clinician may look for something underneath rather than simply treating the surface.
Richer skin tonesTwo things differ. The redness reads as a darker or duskier tone rather than pink and is easily missed, so the colour component is under-recognised. And the marks the plugs leave behind are more likely to be brown than red and to last longer — which is also why the energy-based options at the top of these ladders carry a real pigment-change risk here, and why the practitioner's experience with the skin tone in front of them matters more than the device.
Pregnant, breastfeeding, or planning to beThe ladders shorten from the top down. Topical retinoids and oral isotretinoin come off entirely, elective laser is deferred rather than forbidden, and what remains is the whole non-prescription tier, which is where most of the benefit sits anyway. It is also worth knowing that this condition has been described as arising or worsening in pregnancy, so a flare then is not evidence that something was done wrong.

Look-alikes Not every keratosis pilaris is keratosis pilaris

The single most useful distinguishing feature is time. This condition is stable: the same follicles are plugged this month as last, it does not arrive in crops, and it does not resolve and return. Anything that comes and goes, hurts, or appears for the first time in adulthood deserves a second look, because none of those are how this behaves.

4When the rules changePregnant, breastfeeding, or planning to be · Children and teenagers · Richer skin tones · When it is unusually extensive or has changed

The columns above assume an adult treating a limb with a routine that can simply be adopted. Four situations change that, and in three of them what changes is which rungs are available rather than whether treatment is worth doing.

Pregnant, breastfeeding, or planning to be

The ladders shorten from the top, and the part that carries most of the achievable benefit is untouched. This condition has also been described as arising or worsening during pregnancy, which is worth knowing so that a flare is not read as something having gone wrong.

Still on the table

Emollients and non-soap washes, without qualification
Topical urea, which is widely used in pregnancy for dry-skin conditions
Topical lactic and glycolic acid on the body, generally regarded as compatible at these concentrations
The whole maintenance schedule, which is where the durable benefit sits in any case

Off the table

Topical retinoids, contraindicated as a class
Oral isotretinoin, which is teratogenic and prescribed only inside a mandatory prevention programme
Elective laser and light treatment, customarily deferred rather than forbidden — the benefit is cosmetic and will still be available afterwards

Salicylic acid is the one that needs a real conversation rather than a class answer, because this condition is often treated across a large surface area twice daily, which is exactly the situation in which the usual reassurance about low-concentration topical use applies least.

4Skincare alongside therapyKeeping a treatment tolerable

Supporting care here is unusually load-bearing, because one of its components held its own against a prescription ointment in a blinded comparison. The routine below is not what happens around the treatment on a large area of skin — for a good number of people it is most of the treatment.

Pick the therapy that is underway

Keep everything else gentle and simple. The treatment does the work.

The routine underneath every column

This is the part that stays constant through prescriptions, through a laser course, through pregnancy and through the years in between. It is short, it is dull, and its dullness is the reason it survives.

Shorter, cooler showers, with a non-soap wash used only where it is needed
Emollient onto skin still damp from the shower, within a few minutes rather than an hour later
Enough of it that a large tub is a normal purchase rather than an extravagant one
One keratolytic at a stated percentage, and only one
A monthly photograph from the same window at the same distance

Dry brushes, exfoliating mitts, loofahs, pumice and gritty body polishes
Very hot water and long soaks, which strip faster than any emollient replaces
Fragranced body lotion, which keeps the skin quietly reactive without ever being dramatic
Two acids on the same skin, which makes any reaction unattributable and any result unreadable

A gentle cleanserBrowse all cleansers → An emollient for everywhereBrowse all moisturizers → A barrier moisturizerBrowse all moisturizers →

Applies to

The columns above describe treatment. Where what is wanted is a complete routine built around dry or barrier-impaired skin — including the parts this page leaves out — these start from the same principles. Dry skin routine · Barrier repair routine · Eczema routine

The product roles above link to categories rather than to individual products, and for this condition the category genuinely is the decision — what matters is a stated percentage, an unfragranced base, and a container large enough that the quantity the job needs does not feel extravagant. A cheaper product used generously beats a better one used sparingly, and that is not a compromise but the actual finding.

5What to expectWhy treatments get abandoned

The realistic shape is a clear improvement in texture, a smaller one in colour, and no ending. Twelve weeks of a keratolytic reduced lesions by roughly two-thirds in the controlled trial, and that is what a good result looks like — not clearance. The redness is the part that disappoints, and it disappoints predictably: the trial that improved roughness with a laser found erythema statistically unchanged, and the largest series of the red variant reported minimal improvement across every topical tried. On natural history, the widespread belief that this simply goes away with age is only partly true. In the one survey to follow it, about a third improved with age, over two-fifths were unchanged, and around a fifth had worsened, with the mean age of improvement in the mid-teens. Four in five reported a seasonal swing, most often worse in winter. Knowing all of that in advance converts a frustrating condition into a manageable one; discovering it after two years of escalating products does the opposite.

1The trial that produced the numbers ran twelve weeks
abandoning at four is how a working treatment gets recorded as a failure
2Improvement reverses over weeks to months when treatment stops, which is the condition rather than the product failing
3Maintenance at once or twice weekly is the step almost nobody is told about and the one that decides whether a result holds
4Scrubbing harder is the escalation that reliably backfires, and it targets the half that no treatment reaches
5A result judged across two different seasons is measuring the calendar as much as the treatment

Keeping an eye on itOne photograph a month from the same window at the same distance, plus a note of which product and what frequency. Roughness improves too slowly to register day to day and too quickly to be remembered accurately over a season, and the seasonal swing four in five people report makes month-to-month memory particularly unreliable. Those photographs are also the most useful thing to bring to an appointment, because this condition is entirely legible in a picture and hard to describe in words.

Tools that keep a treatment going

Patch Test TimerIntroducing a keratolytic across both arms and both thighs at once is how a tolerable product becomes an intolerable fortnight.

0On the horizonPhase 3 and newly approved only

Nothing here changes what to do todayNothing in this section changes what is available or advisable today. It is here so that a reader knows what is moving, not so that anyone defers treatment waiting for it.

There is nothing to list, and the reason is structural rather than a gap in the search. This condition is benign, common and classed as cosmetic, which means it attracts almost no commercial drug development — no agent has been taken through a registration programme for it, and none is in one now. Movement is happening in two places instead. Genetics is the more interesting: the association with filaggrin variants and with the barrier defect underlying eczema is being mapped in cross-sectional studies, and understanding why the follicle plugs is a precondition for anything better than dissolving what it produces. The other is device protocols, where sham-controlled trials of laser and light have appeared over the last several years and are the only part of this field where controlled evidence is accumulating at all.

Only treatments in phase 3 trials, submitted to a regulator, or recently approved for this indication. Earlier-stage work is excluded because most of it never arrives, and listing it turns a research programme into an expectation. Last reviewed 2026-09-01.

If anything is ever developed for this

This page is updated when a treatment reaches a regulator or an approval, rather than when a press release describes an early result. For a condition with no commercial development programme, that notification may be a long way off.

We don't sell your address, and we don't send anything else.

25SourcesThe guideline and the studies behind the order

The guideline this pathway follows Keratosis pilaris (and its variants) — clinical guidance (opens in a new tab) Primary Care Dermatology Society (UK) · Primary Care Dermatology Society, last updated October 2024

The guideline this pathway follows Keratosis pilaris: a systematic review of the literature and strategies for optimal treatment (opens in a new tab) European Journal of Dermatology · European Journal of Dermatology, 2025

The guideline this pathway follows Treatment of keratosis pilaris and its variants: a systematic review (opens in a new tab) Journal of Dermatological Treatment · Journal of Dermatological Treatment, 2022

No single guideline stands behind this page, so it rests on primary-care guidance, three systematic reviews and the controlled trials underneath them. Every link below was resolved against the journal record before publication; a citation printed without one could not be confirmed rather than having been left out.

2015 Epidermal permeability barrier in the treatment of keratosis pilaris (opens in a new tab) Kootiratrakarn T, Kampirapap K, Chunhasewee C. · Dermatology Research and Practice The head-to-head lactic acid and salicylic acid figures the whole non-prescription tier rests on.
2025 Keratosis pilaris: a systematic review of the literature and strategies for optimal treatment (opens in a new tab) Beyron A. · European Journal of Dermatology The ladder order, the naming of lactic and glycolic acids as preferred topicals, and the framing of management as centred on explanation.
2022 Treatment of keratosis pilaris and its variants: a systematic review (opens in a new tab) Maghfour J, Ly S, Haidari W, Taylor SL, Feldman SR. · Journal of Dermatological Treatment The finding that energy-based treatment is the most consistently supported modality, and the standing of the topical options.
2020 Light and Laser Treatments for Keratosis Pilaris: A Systematic Review (opens in a new tab) Kechichian E, Jabbour S, El Hachem L, Tomb R, Helou J. · Dermatologic Surgery The total size of the device evidence base, and the statement that no effective long-term treatment exists.
2015 Treatment of keratosis pilaris with 810-nm diode laser: a randomized clinical trial (opens in a new tab) Ibrahim O, et al. · JAMA Dermatology The central claim of this page — roughness improved while baseline erythema did not — and the pigment-change withdrawals.
2020 Innovative 1064-nm Nd:YAG Laser Significantly Improves Keratosis Pilaris, A Randomized, Double-Blind, Sham-Irradiation-Controlled Trial (opens in a new tab) Maitriwong P, Tangkijngamvong N, Asawanonda P. · Lasers in Surgery and Medicine The sham-controlled evidence for the Nd:YAG at the top of the texture column.
2019 Intense Pulsed-light Therapy Significantly Improves Keratosis Pilaris: A Randomized, Double-blind, Sham Irradiation-controlled Trial (opens in a new tab) Maitriwong P, Tangkijngamvong N, Asawanonda P. · The Journal of Clinical and Aesthetic Dermatology The sham-controlled result for intense pulsed light referenced on the vascular card.
2016 Fractional Carbon Dioxide Laser for Keratosis Pilaris: A Single-Blind, Randomized, Comparative Study (opens in a new tab) Vachiramon V, Anusaksathien P, Kanokrungsee S, et al. · BioMed Research International The ablative resurfacing option among the device choices.
2020 Clinical and dermoscopic evaluation of fractional carbon dioxide laser in management of keratosis pilaris in Egyptian type skin (opens in a new tab) Ismail S, Omar SS. · Journal of Cosmetic Dermatology The split-body comparison against topical urea, and evidence in richer skin tones.
2011 A comparative trial comparing the efficacy of tacrolimus 0.1% ointment with Aquaphor ointment for the treatment of keratosis pilaris (opens in a new tab) Breithaupt AD, Alio A, Friedlander SF. · Pediatric Dermatology Both the tacrolimus card and the argument that a plain emollient belongs in the actives list rather than in supporting care.
2004 Tazarotene 0.05% cream for the treatment of keratosis pilaris Bogle MA, Ali A, Bartel H. · Journal of the American Academy of Dermatology The randomised retinoid result covering itch, redness and roughness. Published as a conference abstract, and no indexed record could be resolved for it.
1984 Practical management of widespread, atypical keratosis pilaris (opens in a new tab) Novick NL. · Journal of the American Academy of Dermatology The compounded salicylic-acid-in-urea approach and the only published use of a sponge in this condition.
1994 Natural history of keratosis pilaris (opens in a new tab) Poskitt L, Wilkinson JD. · British Journal of Dermatology Every natural-history figure on this page: site distribution, family history, the seasonal swing, and what actually happens with age.
2006 Keratosis pilaris rubra: a common but underrecognized condition (opens in a new tab) Marqueling AL, et al. · Archives of Dermatology The description of the red variant and the finding that most treatments produced minimal or no improvement in it.
1994 Clinical findings, cutaneous pathology, and response to therapy in 21 patients with keratosis pilaris atrophicans (opens in a new tab) Baden HP, Byers HR. · Archives of Dermatology The scarring column: the age pattern, the scalp involvement, and the limited response across every treatment class.
1994 Keratosis pilaris atrophicans. One heterogeneous disease or a symptom in different clinical entities? (opens in a new tab) Oranje AP, van Osch LD, Oosterwijk JC. · Archives of Dermatology The heterogeneity of the scarring variants and the associated ocular findings.
2022 Keratosis pilaris and filaggrin loss-of-function mutations in patients with atopic dermatitis - Results of a Finnish cross-sectional study (opens in a new tab) Salava A, Salo V, Remitz A. · Journal of Dermatology The barrier-defect association underlying the itchy column and the emollient-first sequence.
2007 The prevalence of cutaneous manifestations in young patients with type 1 diabetes (opens in a new tab) Pavlović MD, et al. · Diabetes Care The prevalence figures quoted for the metabolic association.
2018 Dermal Microflora Restoration With Ammonia-Oxidizing Bacteria Nitrosomonas Eutropha in the Treatment of Keratosis Pilaris: A Randomized Clinical Trial (opens in a new tab) Lee NY, et al. · Journal of Drugs in Dermatology The ammonia-oxidising bacteria entry among the lower-evidence options.
2018 Chlorine Dioxide Complex Cleanser: A New Agent With Rapid Efficacy for Keratosis Pilaris (opens in a new tab) Zirwas MJ, Fichtel J. · Journal of Drugs in Dermatology The chlorine dioxide cleanser entry among the lower-evidence options.
2013 Photopneumatic therapy for the treatment of keratosis pilaris (opens in a new tab) Ciliberto H, Farshidi A, Berk D, et al. · Journal of Drugs in Dermatology The photopneumatic therapy entry among the lower-evidence options.
2022 Keratosis pilaris rubra successfully treated with topical sirolimus: Report of a case and review of the literature (opens in a new tab) Eckburg A, Kazemi T, Maguiness S. · Pediatric Dermatology The topical sirolimus case report described among the lower-evidence options.

Keratosis pilaris: the full therapy pathway

Pick the pattern that matches

Over the counter

Put the scrub down and take a baseline

Change the shower before changing the shelf

One keratolytic, twice daily

Hold it, and resist the additions

Drop to maintenance, and keep it there

The twelve-week checkpoint

Tools that make the check honest

Where the over-the-counter pathway ends

With a prescription

A prescription topical

The therapies at this stop

Energy-based treatment for texture

The therapies at this stop

Prescription topicals aimed at the inflammation

The therapies at this stop

Vascular laser and light

The therapies at this stop

Treating the inflammation, not the plug

The therapies at this stop

A retinoid, and a look at what sits underneath

The therapies at this stop

Prescription topicals, with modest expectations

The therapies at this stop

Oral isotretinoin

The therapies at this stop

The part that decides whether any of it lasts

What holds the line

Living with the half that does not fully answer

What holds the line

Where the emollient outlives everything else

What holds the line

After the process has been stopped

What holds the line

Pack the bag

The questions to ask

Cost, and who to see

The clinic library

Pregnant, breastfeeding, or planning to be

Children and teenagers

Richer skin tones

When it is unusually extensive or has changed

The routine underneath every column

Where hair removal meets a keratolytic

While a prescription topical is running

Around a laser or light course

Tools that keep a treatment going